



Lantheus Holdings, Inc. to Present at the 2019 UBS Global Healthcare Conference

May 7, 2019

NORTH BILLERICA, Mass.--(BUSINESS WIRE)--May 7, 2019-- [Lantheus Holdings, Inc.](#) (the "Company") (NASDAQ: LNTH), the parent company of [Lantheus Medical Imaging, Inc.](#) ("LMI"), a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, today announced that Mary Anne Heino, President and Chief Executive Officer, and Robert Marshall, Chief Financial Officer, will present at the 2019 UBS Global Healthcare Conference at 1:00 p.m. ET on Tuesday, May 21 at the Grand Hyatt New York.

To access a live webcast of the presentation, please visit the [Investors section](#) of the Company's website at www.lantheus.com. A replay of the webcast will be available on the Company's website for 30 days following the live presentation.

About Lantheus Holdings, Inc. and Lantheus Medical Imaging, Inc.

Lantheus Holdings, Inc. is the parent company of LMI, a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products. LMI provides a broad portfolio of products, including the echocardiography contrast agent DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension and TechnoLite® (Technetium Tc99m Generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures. The Company is headquartered in North Billerica, Massachusetts with offices in Puerto Rico and Canada. For more information, visit www.lantheus.com.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20190507005767/en/>

Source: Lantheus Holdings, Inc.

Investors

Mark Kinarney
978-671-8842

Media

Meara Murphy
978-671-8508